Related Experiment Video
Updated: Jun 9, 2026
08:20
Systematic Approach to Identify Novel Antimicrobial and Antibiofilm Molecules from Plants' Extracts and Fractions to Prevent Dental Caries
Published on: March 31, 2021
Iminosugars past, present and future: medicines for tomorrow
Graeme Horne1, Francis X Wilson, Jon Tinsley
1Summit Plc(1), 91 Milton Park, Abingdon, Oxon, OX14 4RY, UK.
Drug Discovery Today
|September 7, 2010
Summary
Second-generation iminosugars (Seglins™) offer improved selectivity and activity for developing new medicines. These carbohydrate mimetics address diverse targets, overcoming limitations of earlier compounds and advancing glycobiology-based drug discovery.
Area of Science:
- Carbohydrate chemistry
- Medicinal chemistry
- Glycobiology
Background:
- Iminosugars are promising carbohydrate mimetics for drug development.
- First-generation iminosugars faced challenges with selectivity and side effects.
- Advancements in glycobiology highlight the potential of iminosugar-based therapeutics.
Purpose of the Study:
- To review the opportunities presented by second-generation iminosugar leads (Seglins™).
- To highlight the improved activity and selectivity of novel iminosugar compounds.
- To discuss the potential of these compounds in targeting previously refractory biochemical pathways.
Main Methods:
- Review of current literature on iminosugar development.
- Analysis of structural diversity and biochemical targets of second-generation iminosugars.
- Assessment of clinical data and therapeutic potential of Seglins™.
Main Results:
- Second-generation iminosugars exhibit enhanced selectivity and broader applicability.
- Novel iminosugar structures demonstrate improved pharmacological profiles.
- These compounds show promise for targeting diverse and challenging biochemical pathways.
Conclusions:
- Second-generation iminosugars (Seglins™) represent a significant advancement in medicinal chemistry.
- These compounds offer a promising avenue for developing more effective and safer therapeutics.
- The continued exploration of iminosugars is crucial for future drug discovery in glycobiology.
Related Concept Videos
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:10Sugars as Energy Storage Molecules
Sugar (a simple carbohydrate) metabolism (chemical reactions) is a classic example of the many cellular processes that use and produce energy. Living things consume sugar as a major energy source because sugar molecules have considerable energy stored within their bonds. Consumed carbohydrates have their origins in photosynthesizing organisms like plants. During photosynthesis, plants use the energy of sunlight to convert carbon dioxide gas into sugar molecules, like glucose. Because this...
01:10Sugars as Energy Storage Molecules
Sugar (a simple carbohydrate) metabolism (chemical reactions) is a classic example of the many cellular processes that use and produce energy. Living things consume sugar as a major energy source because sugar molecules have considerable energy stored within their bonds. Consumed carbohydrates have their origins in photosynthesizing organisms like plants. During photosynthesis, plants use the energy of sunlight to convert carbon dioxide gas into sugar molecules, like glucose. Because this...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...